Trials / Completed
CompletedNCT06103695
Vtama in Psoriasis Patients Being Treated With Biologics.
Open Label, Observational Study, Evaluating VTAMA® (Tapinarof) Cream, 1% QD in Psoriasis Patients Being Treated With Biologic Agents.
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Psoriasis Treatment Center of Central New Jersey · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Open label study to assess 12 weeks of add-on VTAMA® (tapinarof) Cream, 1% QD in patients with ≥3% BSA who have received biologic therapy for at least 24 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tapinarof | Add on Vtama (tapinarof) to biololgic therapy |
Timeline
- Start date
- 2023-02-27
- Primary completion
- 2023-10-18
- Completion
- 2023-10-18
- First posted
- 2023-10-27
- Last updated
- 2023-10-27
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06103695. Inclusion in this directory is not an endorsement.